Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

BACKGROUND: Despite the proven benefits of iron chelation therapy (ICT) in the management of chronic iron overload and related complications, compliance to long-term ICT is challenging. Results from the ECLIPSE study, an open-label, randomized, multicenter, 2-arm, phase 2 study evaluated the safety...

詳細記述

保存先:
書誌詳細
出版年:Exp Hematol Oncol
主要な著者: Tartaglione, Immacolata, Origa, Raffaella, Kattamis, Antonis, Pfeilstöcker, Michael, Gunes, Sibel, Crowe, Susanne, Fagan, Niamh, Vincenzi, Beatrice, Ruffo, Giovan Battista
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2020
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7419189/
https://ncbi.nlm.nih.gov/pubmed/32793403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00174-2
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料